Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW (Phase 2 RAINBOW study NCT05758922). The randomized, double-blind, placebo-controlled study, conducted in Brazil, involved 13 patients older than 12 years who are affected by GM2 gangliosidosis or Niemann-Pick disease type C (NPC). The aim of the RAINBOW study is …
SEARCH RESULT FOR:
Showing: 1 - 3 of 107 RESULTS
7th Annual DART To The Finish Charity Walk * Sat. * Sept. 28, 2024
Gather your friends and family and join is for another invigorating 2-mile walk with beautiful views of Long Island Sound around Tod’s Point in Old Greenwich, and help us raise much needed funds to find a cure for Niemann-Pick type C disease. No beach pass, no problem. DART has you covered! The morning always makes …
IntraBio files New Drug Application for N-acetyl-L-leucine (IB1001) for the treatment of NPC
IntraBio Inc. is pleased to share that the New Drug Application (NDA) for N-acetyl-L-leucine (IB1001) for the treatment of Niemann-Pick disease type C (NPC) was submitted to the US Food and DrugAdministration (FDA) in January 2024. The FDA has a 60-day filing review period to determine whetherthe NDA is complete and accepted for review. With …